PRE-TEST QUESTIONNAIRE
Sunday, September 15th, 2024 | Palm Beach, Florida
Email
*
example@example.com
1. Which of the following tests provides the highest sensitivity and specificity for the diagnosis of bronchiectasis?
*
Chest radiograph
Computed tomography with contrast (contrast CT)
Chest magnetic resonance imaging (MRI)
High resolution computed tomography (HRCT)
Clinical examination and symptom scores
2. Which of the following airway clearance treatments is recommended against in patients with bronchiectasis?
*
Manual chest physiotherapy (CPT)
Acapella / Positive Expiratory Pressure device
Hypertonic saline solution through nebulization
Dornase alpha
Exercise
3. Which cell-type has been implicated in the inflammatory portion of the vicious vortex that has been used to describe the pathophysiology of bronchiectasis, and is targeted by dipeptidyl peptidase 1 (DPP1)?
*
Neutrophils
Mast cells
Lymphocytes
Red blood cells
Goblet cells
4. Brensocatib was shown in a Phase 2 clinical trial to significantly improve all of the following outcomes except:
*
Sputum neutrophil elastase
Mortality
Time to first bronchiectasis exacerbation
Quality of life (St. George’s Respiratory Quotient)
Rate of bronchiectasis exacerbations
5. A patient diagnosed with COPD who has an mMRC score of 2 with no exacerbating events would fall into which GOLD group?
*
Group A (mild symptoms with low risk of exacerbations)
Group B (moderate-to-severe symptoms with low risk of exacerbations)
Group C (mild symptoms with high risk of exacerbations)
Group E (any degree of symptoms with high risk of exacerbations)
6. In the Phase 3 BOREAS trial, treatment with dupilumab was associated with:
*
No changes in COPD exacerbations but a favorable safety profile
Reduced COPD exacerbations in patients with high blood eosinophils but a higher incidence of respiratory infections compared to placebo
Reduced COPD exacerbations in patients regardless of blood eosinophil status and a favorable safety profile
Reduced COPD exacerbations and improved lung function in patients with high blood eosinophils and a favorable safety profile
7. Patient and clinician collaboration in developing a written COPD care plan has been shown to:
*
Improve HRQoL only
Reduce respiratory-related hospital admissions only
Improve HRQoL and reduce respiratory-related hospital admissions
Have no effect on COPD outcomes
Thank you! Please press submit to enter your information.
Submit
Should be Empty: